Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
-
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
-
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
-
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
-
Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387
Trading Information
- Previous Close Price
- $72.98
- Day Range
- $82.26–90.80
- 52-Week Range
- $35.20–90.80
- Bid/Ask
- $88.00 / $90.00
- Shares Outstanding
- 78.57M
- Market Cap
- $6.96B
- Volume/Avg
- 57 / 646,620
Key Statistics
- Price/Earnings (Normalized)
- 84.27
- Price/Sales
- 7.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.23%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 366
- Website
- https://www.kiniksa.com
Valuation
|
Metric
|
KNSA
|
|---|---|
Price/Earnings (Normalized) | 84.27 |
Price/Book Value | 9.86 |
Price/Sales | 7.85 |
Price/Cash Flow | 45.21 |
Price/Earnings
KNSA
Financial Strength
|
Metric
|
KNSA
|
|---|---|
Quick Ratio | 3.12 |
Current Ratio | 3.91 |
Interest Coverage | — |
Quick Ratio
KNSA
Profitability
|
Metric
|
KNSA
|
|---|---|
Return on Assets (Normalized) | 17.13% |
Return on Equity (Normalized) | 23.31% |
Return on Invested Capital (Normalized) | 22.97% |
Return on Assets
KNSA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|mC%K&?# | LOCK|X>DX | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|<^?&dF% | LOCK|d%?t | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|&?>>Tg | LOCK|Z< | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|@K!f@<# | LOCK|!&g | $32B | |||
| Viatris Inc
VTRS
| LOCK|NSlL$z | LOCK|pWr | $22B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|PPk#%s | LOCK|!T | $11B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|^v | LOCK|@^ | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|C@x^^$# | LOCK|J&> | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|Z@CD!f | LOCK|Hc$^ | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|V#V#N#Z | LOCK|Tl | $2B |
United States